ResearcherQueen Mary University of LondonActive in the last 2 years
Elena Tomás Bort
Matched on ORCID iD 0000-0001-7897-8891; OpenAlex author ID A5014401760. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 22
2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 2 papers
Papers 7
- Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. Co-author DOI 10.1016/j.actbio.2025.12.020↗
- Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". First author DOI 10.1016/j.jpet.2026.104305↗
- Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.jpet.2025.103573↗
- Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. Co-author DOI 10.7554/elife.86971↗
- Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13163969↗
- Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. Co-author DOI 10.3390/cells10040847↗
- 3D approaches to model the tumor microenvironment of pancreatic cancer. Co-author DOI 10.7150/thno.42441↗
Closest collaborators
The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Richard Philip Grose · 4 shared papers, 2021–2026 · strength 0.82
- Paper Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". DOI 10.1016/j.jpet.2026.104305↗
- Paper Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. DOI 10.1016/j.jpet.2025.103573↗
- Paper Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. DOI 10.7554/elife.86971↗
- Peter James McCormick · 3 shared papers, 2023–2026 · strength 0.66
- Paper Corrigendum to "Histamine H1 receptor: a potential therapeutic target for pancreatic ductal adenocarcinoma". DOI 10.1016/j.jpet.2026.104305↗
- Paper Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma. DOI 10.1016/j.jpet.2025.103573↗
- Paper Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. DOI 10.7554/elife.86971↗
- Hemant Mahendrakumar Kocher · 3 shared papers, 2021–2026 · strength 0.62
- Paper Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. DOI 10.1016/j.actbio.2025.12.020↗
- Paper Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion. DOI 10.7554/elife.86971↗
- Paper Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer. DOI 10.3390/cells10040847↗
- Daniela Loessner · 3 shared papers, 2020–2026 · strength 0.55
- Paper Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. DOI 10.1016/j.actbio.2025.12.020↗
- Paper 3D approaches to model the tumor microenvironment of pancreatic cancer. DOI 10.7150/thno.42441↗
- Paper Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13163969↗
- Juliana B. Candido · 3 shared papers, 2020–2026 · strength 0.55
- Paper Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells. DOI 10.1016/j.actbio.2025.12.020↗
- Paper 3D approaches to model the tumor microenvironment of pancreatic cancer. DOI 10.7150/thno.42441↗
- Paper Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers13163969↗
- Paul A. Insel · 2 shared papers, 2025–2026 · strength 0.49
- Krishna Sriram · 2 shared papers, 2025–2026 · strength 0.49
- Cristina Salmerón · 2 shared papers, 2025–2026 · strength 0.49
- Jonathan Weitz · 2 shared papers, 2025–2026 · strength 0.49
- Andrew M. Lowy · 2 shared papers, 2025–2026 · strength 0.49
- Hervé Tiriac · 2 shared papers, 2025–2026 · strength 0.49
- Shreya Sharma · 2 shared papers, 2020–2026 · strength 0.43
- Eleonora Peerani · 2 shared papers, 2021–2026 · strength 0.41
- Edward P. Carter · 2 shared papers, 2021–2023 · strength 0.33
- Eleni Maniati · 1 shared paper, 2026 · strength 0.29
- Rodrigo Curvello · 1 shared paper, 2026 · strength 0.29
- Jun Wang · 1 shared paper, 2026 · strength 0.29
- Abigail S. Coetzee · 1 shared paper, 2021 · strength 0.16
- Markus Kieler · 1 shared paper, 2020 · strength 0.15
- Wilko Weichert · 1 shared paper, 2021 · strength 0.12
- Victoria Sanz‐Moreno · 1 shared paper, 2021 · strength 0.12
- Verena Kast · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.